share_log

Oppenheimer Maintains Outperform on TransMedics Gr, Maintains $125 Price Target

Benzinga ·  Dec 3 22:59  · Ratings

Oppenheimer analyst Suraj Kalia maintains TransMedics Gr (NASDAQ:TMDX) with a Outperform and maintains $125 price target.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment